Erratum to: Breast Cancer Res Treat DOI 10.1007/s10549-014-2923-9
Unfortunately, in the original publication of the article, a statement in the third paragraph of the discussion section has been published with an error.
The statement in the discussion currently reads: However, neutropenia did not appear to substantially influence efficacy outcomes; among subjects with or without neutropenia grade 3 or lower (n = 28 in each group), the ORR was 8/28 in each group and median PFS was 208 days (with) compared with 203 days (without).
The correct statement is: However, neutropenia did not appear to substantially influence efficacy outcomes; among subjects with or without neutropenia grade 3/4 (n = 28 in each group), the ORR was 8/28 in each group and median PFS was 208 days (with) compared with 203 days (without).
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s10549-014-2923-9.
Rights and permissions
About this article
Cite this article
McIntyre, K., O’Shaughnessy, J., Schwartzberg, L. et al. Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat 146, 329 (2014). https://doi.org/10.1007/s10549-014-3010-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-014-3010-y